ABL1 F317V

CI-VAR-00001108Explore in graph →NP_005148.2:p.Phe317ValNM_005157.5:c.949T>GClinVar 376120 CIViC 1525 rs1057519773

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 2 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Chronic Myeloid Leukemia, BCR-ABL1 Positive5
ABL1 F317V	Dasatinib	Predictive	C	Supports Resistance	—	rejected	EID4536 In a study of 51 imatinib-resistant chronic myeloid leukemia patients, patients with the F317L or F317V mutation in the ABL1 portion of the BCR-ABL1 gene fusion (n=10) were associated with acquired re… (full text at CIViC) PMID 27485109 · Soverini et al., 2016 · Open in CIViC	civic
BCR::ABL1 Fusion AND ( ABL1 F317L OR ABL1 F317V )	Dasatinib	Predictive	B	Supports Resistance	2	accepted	EID4386 In a study of 51 imatinib-resistant chronic myeloid leukemia patients, 26 patients relapsed on dasatinib. Of these, there were 10 patients with the F317L or F317V mutation in the ABL1 portion of the B… (full text at CIViC) PMID 27485109 · Soverini et al., 2016 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Malignant Neoplasm2
BCR::ABL1 Fusion AND ABL1 F317V	Dasatinib	Predictive	D	Supports Resistance	3	accepted	EID7845 In an in vitro study, a Ba/F3 cell line stably expressing F317V in the ABL1 portion of the BCR-ABL1 fusion protein was associated with resistance to dasatinib treatment (IC50: >2000.0 nM) as compared … (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic
BCR::ABL1 Fusion AND ABL1 F317V	Bafetinib + Imatinib + NilotinibSubstitutes	Predictive	D	Does Not Support Resistance	3	accepted	EID7843 In an in vitro study, a Ba/F3 cell line stably expressing the dasatinib-resistance variant F317V in the ABL1 portion of the BCR-ABL1 fusion protein was associated with similar sensitivity to imatinib,… (full text at CIViC) PMID 18191450 · Deguchi et al., 2008 · Open in CIViC	civic